Remdesivir is authorized for use under an EUA. Only for the treatment of patients with suspected or laboratory-confirmed SARS-CoV-2 infection and severe COVID-19. Severe disease is defined as patients with an oxygen saturation (SpO2) ≤94%. Requiring supplemental oxygen, mechanical ventilation, and/or (ECMO). Remdesivir is authorized for adult or pediatric patients who are admitted to a hospital. For whom use of an IV agent is clinically appropriate. Remdesivir must be administered intravenously.